This brand name is authorized in Ecuador, Israel, Turkey
The drug IXIFI contains one active pharmaceutical ingredient (API):
|
1
Infliximab
UNII B72HH48FLU - INFLIXIMAB
|
|
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L04AB02 | Infliximab | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 214-MBE-0821 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8568 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8681308771018 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
